Site-directed mutagenesis guided by evolutionary trace analysis revealed that substitution of V179 and W183 within a cluster of evolutionarily important residues on the surface of the fourth transmembrane domain of the β 1 -adrenergic receptor (β 1 AR) significantly reduced the propensity of the receptor to self-assemble into homodimers as assessed by bioluminescence resonance energy transfer in living cells. These results suggest that mutation of V179 and W183 result in conformational changes that reduce homodimerization either directly by interfering with the dimerization interface or indirectly by causing local misfolding that result in reduced self-assembly. However, the mutations did not cause a general misfolding of the β 1 AR as they did not prevent heterodimerization with the β 2 AR. The homodimerization-compromised mutants were significantly retained in the endoplasmic reticulum (ER) and could not be properly matured and trafficked to the cell surface. Lipophilic β-adrenergic ligands acted as pharmacological chaperones by restoring both dimerization and plasma membrane trafficking of the ER-retained dimerization-compromised β 1 AR mutants. These results clearly indicate that homodimerization occurs early in the biosynthetic process in the ER and that pharmacological chaperones can promote both dimerization and cell surface targeting, most likely by stabilizing receptor conformations compatible with the two processes.
membrane proteins have been suggested to play important roles at different steps of this process (2) (3) (4) (5) (6) (7) (8) . More specialized chaperones and escort proteins have also been found to be involved for specific GPCRs (9) (10) (11) (12) (13) (14) (15) .
In addition to these interactions with general or specialized chaperones, homo-and heterodimerization of GPCRs have also been proposed to play a role in their folding and export to the cell surface. The most dramatic demonstration to date for a role of dimerization in GPCR cell surface trafficking comes from studies on a member of the family C GPCRs, the metabotropic GABA B receptor (GABA B ), demonstrating that heterodimerization between GABA B1 and GABA B2 is essential for proper targeting of a functional GABA B to the plasma membrane (16) . In that case, dimerization involving a coiled-coil interaction between the carboxyl tails of the two receptors is necessary to hide an ER retention signal located in the cytoplasmic tail of GABA B1 thus permitting the targeting of the dimeric receptor at the cell surface.
Although no such ER retention signal or direct evidence for coiled-coil interaction of their carboxyl tails were found for family A GPCRs, increasing data suggest that homo-and heterodimerization of members of family A GPCRs can also occur in the ER and be involved in receptor biogenesis and quality control of newly synthesized receptors (17) . For example, mutations that were found to prevent homodimerization of the β 2 -adrenergic receptors (ARs) (18) or the α 1b AR (19, 20) also led to their retention in the ER, suggesting a link between dimerization and ER exit. Also, heterodimerization with either the α 1b AR (21) or the β 2 AR (22) has been proposed to be necessary for the cell surface trafficking of the α 1d AR. However, the lack of knowledge about the molecular determinants of class A GPCR dimerization has limited our ability to explore the links between receptor dimerization and their trafficking.
For class A GPCRs, information gathered from cross-linking studies of the D2 dopamine receptor (23, 24) , transmembrane (TM) domain competition for the β 2 -adrenergic, D2 dopamine and α 1b -adrenergic receptors (25) (26) (27) , as well as site-directed mutagenesis of the α-mating factor, β 2 -adrenergic, CCR5 chemokine and α 1b -ARsβ 2 -adrenergic, CCR5 chemokine and α 1b -adrenergic receptors (18, 19, 28, 29) , suggested the involvement of various TM domains in the dimerization process (helix I and IV being most frequently implicated). Although these studies provided information about potential domains involved in class A GPCR self-assembly, much remains to be learned about the structural organization of the dimers and in particular concerning the specific residues involved in the dimerization interfaces for different receptors.
One bioinformatics approach recently developed to identify residues that may play important roles in protein structure, function or defining specific protein-protein interaction is known as evolutionary trace (ET) analysis. ET exploits the fact that the sequence variations of functional site residues tend to correlate more tightly with evolutionary divergences than residues with lesser functional impact (30) . As a result, sequence analysis may be combined with protein structure information to rank residues by the extent of their phylogenetic correlation and then identify geometric clusters of top-ranked residues that may then predict functional sites in the protein structure that are common to the entire protein family (31) . The identification of such clusters has successfully allowed the unraveling of important functional domains in several classes of proteins (32, 33) . Particularly relevant to the present study, clusters of residues on the surface of proteins have been proposed to be likely sites for protein-protein interaction (34) and thus could be involved in oligomerization processes. It should also be noted that studies targeting substitutions of top-ranked ET residues repeatedly enabled modulation of function (35) (36) (37) (38) (39) or separation of function (33, 40) , suggesting that specific sites could be altered or blocked through point mutations without leading to global perturbation of the protein fold.
In recent years, treatment with pharmacological chaperones has been shown to rescue the proper plasma membrane targeting of mutant forms of GPCRs that are otherwise retained in the ER (41) . By binding to the intracellularly retained receptors, these lipophilic ligands are believed to stabilize receptor conformations that can then enable them to escape from the ER quality control system, reach the plasma membrane and be functional. In the cases of GPCR mutations leading to disease as a result of ER retention, pharmacological chaperones represent promising therapeutic avenues (42) (43) (44) . In the context of studying the link between folding, dimerization and cell surface targeting, pharmacological chaperones could represent useful tools for the design of gain of function experiments whereby the effects of pharmacological chaperones could be assessed on both the propensity of the receptor to self-assemble and to be trafficked to the cell surface.
In this context, we used ET analysis to guide site-directed mutagenesis aimed at identifying residues involved in the homodimerization of the class A GPCR β 1 AR and tested the effect of mutating these residues on both dimerization and receptor trafficking. The ability of lipophilic β-adrenergic ligands to act as pharmacological chaperones on the ER-retained dimerizationcompromised β 1 AR mutants was also assessed.
Results
To identify sites that could be important in directing protein-protein interactions of bioamine class A GPCRs, 139 receptor sequences, including 26 β-adrenergic, 29 α-adrenergic, 30 serotonergic, 30 dopaminergic, 18 cholinergic muscarinic and 6 histaminic GPCRs, were traced with the ET method (30, 45) . The list and accession number of all sequences used for the analysis are provided in the Supporting Information Table S1 . The analysis was restricted to the TM domains because of their proposed role in dimerization and to reduce confusion that could result from the identification of domains involved in interactions with cytoplasmic and extracellular receptor partners. The ET produces a relative ranking of evolutionary importance among residues, where 1 is best and indicates absolute invariance (46) . TM residues ranking in the top 50% mapped mostly to the structural core of the receptor (47) , but some of these residues also delineated three clusters on the outward, lipid-facing surface of the receptor (Figure 1 ). The first cluster included residues in TM2, TM3 and TM4 whereas the other two were composed of residues within TM5, TM6 and TM7. Because several conserved residues within clusters 2 and 3 have been proposed to be important for ligand binding and signaling functions for many class A GPCRs (48-53), we focused our search for putative protein-protein interaction sites in cluster 1 to avoid possible confounding effects that could result from mutating residues directly involved in ligand binding and signaling. Four residues with different relative ET rankings (L105, V179. W183, I194) were selected for mutagenesis. Their positions on the surface of the β 1 AR as well as their ET rankings are shown in Figure 1 . To make sure that the mutations would result in significant modification of the protein surface shape, we replaced the aliphatic residues (e.g., leucine, isoleucine, and valine) with bulky aromatic amino acids (e.g., tryptophan or phenylalanine) and the bulky tryptophan residue by the small alanine.
To assess the effect of the selected mutations on receptor dimerization, bioluminescence resonance energy transfer (BRET) studies assessing the propensity of the receptor to selfassemble were carried out. For this purpose, wild type (WT) and mutant forms of the β 1 AR were fused to the energy donor, Renilla luciferase (Rluc), and the blue-shifted green fluorescent protein (GFP-10) (54) energy acceptor. GFP10-and Rluc-fused WT or mutant receptors were then co-expressed in HEK293 cells, and the occurrence of BRET determined and used as a reporter for receptor self-assembly. BRET experiments were performed in a titration format, where the amount of transfected β 1 AR-Rluc is maintained constant while the amount of β 1 AR-GFP10 is gradually increased, allowing to assess the relative propensity of WT versus mutant receptors to self-assemble (18, 55) . As shown in Figure 2A , the BRET signal between β 1 ARRluc and β 1 AR-GFP10, expressed as a function of the GFP10/Rluc ratios, increased hyperbolically as a function of the increased expression of β 1 AR-GFP10. The selectivity of the signal observed is illustrated by the reduction in the BRET signal observed upon coexpression of hemagglutin (HA)-tagged β 1 AR (not fused to either Rluc or GFP10) that act as a BRET competitor by interacting with either β 1 AR-Rluc or β 1 AR-GFP10, thus preventing interaction between the BRET partners and blunting the energy transfer (Supporting Information Figure S1 ).
From the BRET titration curves, BRET 50 values corresponding to the concentration of β 1 AR-GFP10 needed to generate 50% of the maximal BRET signal were used as an index of the relative propensity of the protomers to self-assemble. As can be seen in Figure 2 , mutations of L105 and I194 to phenylalanine and tryptophan residues, respectively (L105F, I194W), modestly reduced the maximal BRET signal but did not affect the BRET 50 value, indicating that these mutations did not significantly affect the dimerization propensity of the β 1 AR. In contrast, mutations of V179 and W183 to tryptophan and alanine residues, respectively (V179W, W183A), caused a significant (P < 0.01) rightward shift of the BRET titration curves (Figure 2A ), resulting in 6.1-and 7.0-fold higher BRET 50 values when compared with WTβ 1 AR ( Figure 2B ). Mutation of W183 to a phenylalanine residue (W183F) led to a similar (7.3-fold) increase in BRET 50 value, indicating that substituting a residue smaller than the tryptophan but significantly bulkier than alanine was sufficient to promote the decrease in protomers self-assembly. The increased BRET 50 did not result from non-specific destabilization of the protein because destabilizing mutations should equally affect the receptor fused to the donor and acceptor, and thus should not affect the relative acceptor/donor concentration and hence not change the BRET 50 . Therefore, our results suggest that mutations at positions V179 and W183 in TM4 decrease the propensity of the receptor to self-assemble into a dimer.
Combining the two mutations in the same construct, led to further disruption of the receptor self-assembly as reflected by the much smaller BRET signals and a titration curve that did not converge to an asymptote (Supporting Information Figure S2 ), indicating that this double mutant receptor could not dimerize and that the small BRET signal observed represented nonsaturable random collision events known as bystander BRET (55) . This double mutation also resulted in greater protein instability and was not studied any further because of its low steadystate expression levels.
In all BRET titration experiments, the expression levels of the β 1 AR-Rluc and β 1 AR-GFP10 constructs were monitored by measuring the total luminescence and fluorescence signals. These signals can then be transformed into femtomoles of receptors/sample using titration curves correlating the luminescence and fluorescence signals to the number of receptor binding sites as determined by radioligand binding assays using [ 3 H]-dihydroalprenolol as the tracer (Supporting Information Figure S3 ). The titration experiments were designed to compare BRET values generated over similar acceptor/donor (GFP10/Rluc) ratios but the absolute total number of receptor expressed varied between the different constructs. The expression level distributions for the WT and all mutants are presented in Supporting Information Figure S4 . Although BRET signals are largely determined by the energy donor/acceptor ratios, they can also be influenced by the density of the partner proteins (55, 56) . As shown in Supporting Information Figure S4 , the expression levels for V179Wβ 1 AR, W183Fβ 1 AR and W183Aβ 1 AR were significantly lower than that of the WT receptor. Thus, to exclude a possible role of receptor density on the detected increase in BRET 50 , additional transfection conditions were chosen to generate equivalent expression levels for the WT-and W183Aβ 1 AR. In BRET titration experiments shown in Figure 3 , the WT-and W183Aβ 1 AR expression levels varied between 14-402 and 10-636 fmol, respectively. As was the case in Figure 2 , the titration curve for W183Aβ 1 AR was significantly right-shifted compared with that of the WT receptor, yielding an 8.1 × higher BRET 50 . This confirmed that the increase in BRET 50 resulted from a reduced propensity of the mutant receptor to self-assemble and not from reduced receptor expression levels. Given that homodimerization of the β 1 AR can be detected at physiological expression levels as low as 100 fmol/mg of protein, these results also demonstrate that dimerization does not result from forced interactions caused by receptor over-expression. The representation of the BRET curve as a function of GFP10/Rluc molar ratios (deduced from the standard curves shown in Supporting Information Figure S3 ) also revealed that BRET was detected at very low molar ratio of energy donor/acceptor (BRET 50 molar ratio of 0.6 for WT β 1 AR), which is consistent with the occurrence of constitutive homodimerization.
To assess whether the mutation is needed on each protomer to affect self-assembly, we then assessed the influence of the W183A mutation on the ability of the receptor to interact with either WTβ 1 AR or the β 2 AR that is known to heterodimerize with the β 1 AR (55) . As can be seen in Figure 4 , the W183Aβ 1 AR mutation significantly inhibited the ability of the receptor to interact with the WTβ 1 AR, as illustrated by the 4.7-fold increase in BRET 50 . However, the mutation did not affect the ability of the β 1 AR to heterodimerize with the WTβ 2 AR, as indicated by the identical BRET 50 values obtained for the WTβ 2 AR-Rluc/W183Aβ 1 AR-GFP10 and WTβ 2 AR-Rluc/WTβ 1 AR-GFP10 pairs. The observation that the mutation affected assembly with the WTβ 1 AR but not WTβ 2 AR indicates that mutation of W183 within a single protomer is sufficient to affect β 1 AR homodimerization but not β 1 AR/β 2 AR heterodimerization, and thus that β 1 AR homo-and heterodimerization may involve distinct domains and/or that the conformational changes promoted by the mutation affected the homodimerization but not the heterodimerization interface. This preserved ability of W183Aβ 1 AR to hetrerodimerize with β 2 AR also suggests that if the decreased propensity of the β 1 AR to homodimerize resulted from local misfolding, the mutation did not lead to a global destructuration of the receptor organization.
We next examined the effects of the cluster 1 mutations on the subcellular distribution of the β 1 AR-eGFP constructs by fluorescence confocal microscopy. As for the WT receptor, mutant β 1 ARs that preserved their propensity to self-assemble (L105F and I194W) were largely found at the cell surface. In contrast, mutations that reduced receptor dimerization (V179W, W183F and W183A) lead to intracellular retention of the receptor ( Figure 5 ). It was previously reported that cell-permeable ligands can rescue cell surface expression of ER-retained GPCRs through their action as pharmacological chaperones that bind to the neo-synthesized receptors and favor their export from the ER (42) . Although no pharmacological chaperone has been described for the β 1 AR yet, the fact that the high affinity β-adrenergic antagonist alprenolol can readily permeate lipid membranes makes it a likely candidate as a β 1 AR pharmacological chaperone. We thus assessed whether treatment with alprenolol could rescue cell surface targeting of W183Aβ 1 AR. As can be seen in Figure 6A , in the absence of treatment, W183Aβ 1 AR is largely retained inside the cell where it co-localizes with the ER-resident protein, calnexin, confirming that the major site of retention of the dimerization-compromised mutant is the ER. Treatment of the cells for 24 h with alprenolol favored the plasma membrane targeting of W183Aβ 1 AR, as indicated by the clear redistribution of receptor labeling from the ER to the cell surface. To quantify the subcellular redistribution promoted by alprenolol, the proportion of the total receptor population expressed at the cell surface was determined by a ratiometric enzymelinked immunosorbent assay (ELISA)/luciferase activity assay. For this purpose, a W183Aβ 1 AR construct harboring an HA epitope at its extracellular N-terminal and Rluc at its intracellular C-terminal (HA-W183Aβ 1 AR-Rluc) was used. HA-immunoreactivity detected in non-permeabilized cells is used as an indicator of cell surface receptor expression, whereas the luciferase activity measured upon addition of the cell-permeable substrate, coelenterazine h, reflects the total receptor expression. The immunoreactivity/luciferase ratio is then used as an index of the cell surface targeting efficacy. As shown in Figure 6B , the surface targeting efficacy of W183Aβ 1 AR was 11 ± 0.36% of that of WTβ 1 AR under control conditions. This efficacy was restored to 43 ± 7.4 and 60 ± 12% of that of the WT following alprenolol treatment for 4 and 24 h, respectively.
The ability of alprenolol to act as a pharmacological chaperone for W183Aβ 1 AR was further investigated by assessing the effect of alprenolol on the maturation state of the receptor. As shown in Figure 6C , western blot analysis of β 1 AR reveals three major bands at 47, 52 and 70 kDa. The 52 kDa core-glycosylated form that can be deglycosylated by endoglycosidase H (endoH) treatment represents the precursor form of the receptor before it exits the ER. The 70 kDa form, resistant to endoH treatment, corresponds to the mature receptor with complex sugar acquired in the Golgi, whereas the 47 kDa form observed in the absence of endoH treatment most likely represents a deglycosylated form of the receptor targeted for degradation (1). This deglycosylated form becomes more abundant following treatment with endoH as a result of the deglycosylation of the 52 kDa species. Fainter and poorly resolved bands above 110 kDa most likely represent residual dimeric receptor forms that resisted SDS denaturation. When considering W183Aβ 1 AR, only the core-glycosylated immature and deglycosylated forms of the receptor are observed. This is consistent with the confocal microscopy images indicating that the mutation leads to retention of the receptor in the ER. Alprenolol treatment considerably stabilized the W183Aβ 1 AR precursor form, as can be seen by the increased immunoreactivity of the 52 kDa. More importantly, alprenolol favored ER exit as indicated by the appearance of the endoH resistant, fully glycosylated 70 kDa form of the receptor. Taken together, these results demonstrate that alprenolol acts as an efficacious pharmacological chaperone for the W183Aβ 1 AR, most likely by binding to the mutant receptor in the ER and promoting its maturation.
To determine whether the maturation and cell surface expression rescue was accompanied by a change in the dimerization status of the receptor, we assessed the effect of alprenolol on the self-assembly propensity of W183Aβ 1 AR by performing BRET titration curves. As shown in Figure 7A , treatment with alprenolol for extended periods of time significantly affected the curves. Treatments led to a time-dependent leftward shift in the BRET titration curves, yielding significant reduction in the BRET 50 values that became statistically significant following a 12-h treatment ( Figure 7B ), indicating that alprenolol increased the propensity of W183Aβ 1 AR to dimerize. The small increase in BRET 50 observed after short time treatment with alprenolol did not reach statistical significance. Treatment with alprenolol also led to a significant increase in steady-state receptor levels, increasing from a range of 53-916 fmol/sample for titration curves performed in control conditions to a range of 452-1813 fmol/sample for titrations carried out following 12 or 24 h treatments with alprenolol. However, these changes in expression levels did not account for the decrease in BRET 50 (BRET 50 : 4.1 in control condition; 0.56 following a 24-h treatment with alprenolol), because titration curves obtained from transfections covering similar ranges of expression levels for W183Aβ 1 AR (10-636 versus 115-1968 fmol/mg) in the absence of treatment did not show any significant differences in BRET 50 (data not shown).
The ability of alprenolol to promote W183Aβ 1 AR self-assembly was concentration dependent, with an EC 50 value of 180 nM ( Figure 7C ). This EC 50 value is somewhat higher than the binding affinity values obtained from radioligand binding assays (e.g., 3.9-4.2 nM, (57) ). This difference is compatible with what was previously reported for the apparent potency of pharmacological chaperones that are generally lower than their binding affinities for the WT receptors (58, 59 ). This lower apparent potency could reflect a loss of binding affinity for alprenolol resulting from a conformational effect of the mutation.
Interestingly, co-expression of the W183Aβ 1 AR with the WTβ 2 AR led to the intracellular retention of the latter ( Figure 8A,B) , presumably as a result of its association with the intracellularly retained mutant β 1 AR. This confirms the preserved ability of W183Aβ 1 AR to heterodimerize with the β 2 AR. In contrast, co-expression of W183Aβ 1 AR with WTβ 1 AR did not lead to the retention of WTβ 1 AR ( Figure 8B ), consistent with the decreased propensity of W183Aβ 1 AR to associate with the WTβ 1 AR (Figure 4 ; 4.7-fold increase in BRET 50 when compare with WTβ 1 AR self-assembly). Although this reduced propensity was not as dramatic as the one observed for W183Aβ 1 AR homodimerization (Figure 2 ; 7.0-fold increase in BRET 50 ), it was sufficient to prevent ER retention of WTβ 1 AR. Treatment of cells coexpressing W183Aβ 1 AR and WT β 2 AR with alprenolol restored the plasma membrane targeting of the β 2 AR (Figure 8A) , most likely as a result of the rescue of the retained W183Aβ 1 AR/β 2 AR heterodimer. The co-expression of the β 2 AR did not affect the dimerization pattern of either WTβ 1 AR (Supporting Information Figure S5 ) or W183Aβ 1 AR ( Figure 8C ). In addition, treatment with alprenolol promoted a reduction in the BRET 50 determined for W183Aβ 1 AR-Rluc/W183Aβ 1 AR-GFP10 homodimer even in the presence of β 2 AR. These results clearly indicate that the β 2 AR does not compete with β 1 AR homodimerization, consistent with the notion evoked earlier that β 1 AR homodimerization and β 1 /β 2 AR heterodimerization probably involve distinct interfaces. The absence of competition between β 2 AR and β 1 AR homodimerization combined with the restored cell surface expression of the WTβ 2 AR/W183Aβ 1 AR heterodimer upon pharmacological chaperone treatment may suggest the existence of higher order oligomers composed of both β 1 AR and β 2 AR dimers, as was recently suggested for other class A receptors (60, 61) .
To test whether other β-adrenergic ligands could affect the dimerization propensity of W183Aβ 1 AR, the effect of seven compounds was assessed on the BRET 50 of the W183Aβ 1 AR-Rluc/W183Aβ 1 AR-GFP10 pair. Five of the seven compounds led to significant reductions in BRET 50 ( Figure 9A ). The only two compounds not affecting the BRET titration curve were isoproterenol and atenolol, two compounds with low hydrophobic character that most likely cannot penetrate lipid membranes. In fact, excellent correlations were found between the ability of the compounds to affect the self-assembly of the W183Aβ 1 AR (BRET 50 ) and both their relative membrane permeability estimated by the calculated logP (r 2 = 0.82) and their affinity for the β 1 AR (r 2 = 0.90), consistent with the notion that the ligands need to penetrate the cell and bind the receptor to have their pharmacological chaperone action. The pharmacological selectivity of action is further illustrated by the observation that, in contrast to β-adrenergic ligands, treatments for 24 h with SR121463 or naltrexone, known pharmacological chaperones for the V2-vasopressin (58) and δ-opioid (59) receptors, respectively, did not affect the BRET 50 observed for the W183Aβ 1 AR-Rluc/W183Aβ 1 AR-GFP10 pair ( Figure 9B ). Immunofluorescence microscopy revealed that the effect of the compounds on the BRET 50 is a good predictor of their ability to rescue cell surface expression of W183Aβ 1 AR ( Figure 9C) . Indeed, isopreterenol, atenolol and metoprolol that had either no or modest effect on the BRET 50 did not readily promote detectable trafficking of the receptor to the cell surface whereas all other adrenergic compounds had robust effects on the BRET 50 and clearly restored cell surface expression.
To further explore whether the action of the pharmacological chaperone on dimerization occurs in the early phase of receptor ontogeny, we tested the effect of an inhibitor of ER-golgi transport, brefeldin A. By promoting the fusion of the cis-Golgi with the ER, brefeldin A treatment allows to assess whether the pharmacological chaperone can act on dimerization before trans-Golgi processing. As shown in Figure 10 , a 6-h treatment with alprenolol led to a significant reduction of the BRET 50 for the W183Aβ 1 AR-Rluc/W183Aβ 1 AR-GFP10 pair in the presence and absence of brefeldin A. Given that the brefeldin A treatment completely blocked the alprenolol-promoted cell surface targeting of the receptor (data not shown), these results indicate that alprenolol favors the self-assembly of W183Aβ 1 AR before it exit the cisGolgi, most likely in the ER.
To verify whether the alprenolol-promoted dimerization and cell surface expression of the W183Aβ 1 AR resulted into functionally active receptors, the ability of the selective β 1 AR agonist dobutamine to stimulate cyclic AMP (cAMP) production was assessed. As shown in Figure 11 , in the absence of alprenolol pre-treatment, dobutamine stimulated a robust concentration-dependent cAMP production in cells expressing the WTβ 1 AR but only a very modest response at the highest agonist concentrations in cells expressing W183Aβ 1 AR. This is consistent with the observation that W183Aβ 1 AR is poorly targeted to the plasma membrane. In contrast, dobutamine promoted a similar concentration-dependent cAMP response for both WTβ 1 AR and W183Aβ 1 AR expressing cells following pre-treatment with alprenolol, indicating that, in addition to promote dimerization and cell surface targeting, the pharmacological chaperone action of alprenolol restored the signaling properties of W183Aβ 1 AR. The somewhat smaller response observed in both WTβ 1 AR and W183Aβ 1 ARexpressing cells following alprenolol pre-treatment, when compared with non-pretreated WTβ 1 AR-expressing cells, most likely results from incomplete washout of alprenolol before the dobutamine challenge.
Discussion
Our data clearly demonstrate that mutations of two residues (V179 and W183) located in TM4 of the β1AR had profound effects on the self-assembly capacity of the receptor. Substitution of V179 to tryptophan or of W183 to either alanine or phenylalanine significantly increase the BRET 50 of the β 1 AR homodimer without affecting the maximal BRET signal reached. BRET 50 being a reflection of the protomers' propensity to self-assemble (55) , it follows that V179W, W183A and W183F mutations most likely affected the ability of individual molecules of β 1 AR to form dimers without completely inhibiting dimerization.
Although the mutated residues were identified as part of a cluster present at the surface of the receptor that could be involved in protein-protein interactions, our data do not allow to conclude that V179 and W183 are directly involved in the homodimerization interface. Indeed, conformational changes leading to local misfolding that indirectly affect dimerization could also underlie the effects of the mutations. In fact, the recently resolved crystal structure of the turkey β1AR (62) indicates that the residues corresponding to V179 and W183 in the human β1AR establish contact with the backbone of the TM2 and may stabilize the local orientation of the two TM surfaces. Mutation of these residues may thus locally destabilize the structure of the receptor. Consistent with such a conformational effect is the observation that the concentration of alprenolol required to act as a pharmacological chaperone on the mutant receptors is much higher than the affinity of the ligand for the WT receptor (180 versus 1-10 nM) indicating that the mutation may have indirectly affected the binding pocket. However, several lines of evidence indicate that the reduced homodimerization did not result from global receptor misfolding. First, W183Aβ 1 AR preserved a normal ability to heterodimerize with the β 2 AR indicating that the mutation selectively prevented homodimerization. Also, the mere fact that alprenolol, carvedilol, labetalol and propranolol acted as pharmacological chaperone indicates that the mutant receptor maintained a ligand binding pocket that allows binding, albeit maybe with lower affinity, of these small ligands. Finally, W183Aβ 1 AR rescued by the pharmacological chaperone could efficiently respond to agonist stimulation by triggering G protein signaling. Nevertheless, whether the loss of dimerization resulted from the mutation of residues directly involved in the homodimerization interface or from local misfolding cannot be ascertain from our data.
Our results are in agreement with a growing consensus suggesting that TM4 residues may play important roles in class A GPCR dimerization (63) . However, several other TM domains have also been proposed to participate into both homo-and hetero-oligomerization (23, 26, 27, 64, 65) , and it is likely that several points of contact located on different TM domains contribute to the quaternary structure arrangements of receptor homo and heterodimers. It is also likely that different receptors may use distinct domains to dimerize. Consistent with this notion, mutation of W158 to alanine in the β 2 AR (corresponding to W183 in the β 1 AR) did not affect its homodimerization BRET 50 (data not shown). This could suggest that different receptors even as closely related as the β 1 AR and β 2 AR use different dimerization interfaces or that the mutation has different conformational consequences for β 1 AR and β 2 AR. The observation that over-expression of β 2 AR did not compete with β 1 AR homodimerization is consistent with the first possibility. Clearly, additional work will be necessary to have a clearer picture of the threedimensional organization of various homo and heterodimers.
Independent of the mechanism underlying the effect of the mutations on dimerization, our results clearly show that the three mutations affecting self-assembly of the β 1 AR (V179W, W183A and W183F) also greatly reduced cell surface targeting of the receptor as a result of its retention in the ER. In contrast, mutations of the nearby residue I194 in TM4 (I194W) or L105 in TM2 (L105F), which did not affect dimerization, were without effect on receptor trafficking. This apparent correlation between dimerization propensity and ER-export is consistent with an increasing number of studies indicating that dimerization occurs in the ER for many class A GPCRs, including the β 2 -adrenergic (18), vasopressin V2 (56), melanocortin MC1 (66) and serotonin 5HT 2C (67) receptors. In one of these studies, mutations in TM6 were found to reduce the propensity of the β 2 AR to self-assemble and to be targeted to the cell surface, leading to the suggestion that dimerization could play a role in the ER quality control system of newly synthesized proteins and their export to the cell surface. Similar propositions were made following the observation that mutations in TM1 and TM4, which prevented α 1b AR dimerization, led to ER retention (19, 20) . Such a role for oligomerization in the ER quality control of GPCRs would not be surprising because protein-protein interactions, including both homo-and heterodimerization, have often been shown to play prominent roles in the quality control of many proteins (68) .
One of the difficulties in establishing a causal link between dimerization and receptor trafficking from mutagenesis study is to exclude the possibility that both the loss in dimerization and cell surface targeting may result from misfolding of the receptor caused by the mutation and thus may not indicate a causal relationship between dimerization and trafficking, both dimerization and cell surface trafficking being independently affected by the conformational change imposed by the mutations.
The ability of lipophilic ligands to favor the folding and cell surface expression of ER-retained proteins has been previously shown for several GPCRs and is referred to as pharmacological chaperoning (42) . Pharmacological chaperones bind to ER-retained proteins and favor their escape from the ER quality control system, allowing trafficking to their proper site of action. It is believed that ER-retained proteins that can be rescued by pharmacological chaperones bear relatively modest mutations that, although recognized by the quality control systems as improperly or incompletely folded, can still reach near-native conformations that are stabilized by the binding of the pharmacological chaperone; hence, their release from the ER. Alprenolol clearly acted as a pharmacological chaperone on W183Aβ 1 AR as it promoted receptor maturation from its ER-located core-glycosylated form to fully glycosylated species, reflecting Golgi processing and resulting in cell surface targeting. Interestingly, this action of alprenolol correlated with a restoration of the receptor's propensity to self-assemble, as reflected by the time-dependent reduction in BRET 50 observed upon alprenolol treatment. The effects of alprenolol on dimerization and cell surface expression had similar kinetics that are consistent with pharmacological chaperoning. The link between the pharmacological chaperoning effect of alprenolol and its ability to promote receptor dimerization is further supported by the observation that alprenolol promotes dimerization while the receptor is still in the ER. Indeed, brefeldin A treatment, which prevents ER exit, did not block the alprenolol-induced decrease in W183Aβ 1 AR BRET 50 . The good correlation between the lipophilic character of the various βAR ligands tested and their ability to restore β 1 AR self-assembly is also compatible with the notion that they need to penetrate biological membranes to have their action in the ER. Collectively, these findings are consistent with many other studies indicating that GPCR oligomerization occurs early after biosynthesis, most likely in the ER (17) . During the revision of the present manuscript, a study reported that α-adrenergic ligands that act as pharmacological chaperones for the cell surface targeting of ER-retained α 1B AR mutants also restored receptor homodimerization (20) , suggesting that action of pharmacological chaperone on receptor selfassembly may be a general feature of pharmacological chaperone action.
How pharmacological chaperones restores dimerization of the receptor remains to be determined. Given that the W183A mutation was found to reduce but not abolish the propensity of the β 1 AR to self-assemble and that the effect may result either from a local misfolding of the receptor or from a direct effect on the dimerization interface, two possible and nonexclusive models can be proposed: (i) the pharmacological chaperone binds to a monomeric form of the receptor that has a reduced propensity to dimerize, as a result of a local misfolding promoted by the mutations, and stabilizes a near-native conformation of the receptor that can now dimerize more readily and (ii) the pharmacological chaperone binds to a dimeric receptor form that has been destabilised by the mutations and, through ligand binding energy, stabilizes the dimeric complex, hence driving the monomer/dimer equilibrium towards dimerization. These two possibilities are difficult to differentiate experimentally with the currently available techniques. Dimerization can also be seen as a component of the overall receptor folding, making it even more difficult to distinguish effects that are specific to the dimerization process. Whether the dimerization-promoting action of the pharmacological chaperones is part of their mode of action to promote ER-export of the receptor or simply a consequence of the stabilization of the receptor's native conformation also remains to be determined. Nevertheless, we can conclude that alprenolol has positive effects on both homodimerization and ER-export of the receptor, thus linking the two phenomena in a gain of function paradigm.
The sequence of events linking folding, dimerization and ER-export as well as the precise mode of action of the pharmacological chaperone still remains to be clarified.
Materials and Methods

Materials
Dulbecco's modified Eagle's medium, penicillin-streptomycin, L-glutamine and phosphatebuffered saline (PBS) were obtained from Wisent. Leupeptin, benzamidine, soybean trypsin inhibitor, Phenylmethanesulfonyl fluoride, (-)-alprenolol, (-)-isoproterenol, dobutamine, S-(-)-atenolol, (±)-metoprolol, DL-propranolol and labetalol were purchased from Sigma-Aldrich. Carvedilol is a generous gift from GlaxoSmithKline. DeepBlueC coelenterazine was purchased from Biotium Inc. Coelenterazine h was purchased from Nanolight Technology. Brefeldin A was purchased from Calbiochem. Horseradish peroxidase-conjugated rat anti-HA antibody (3F10) and FuGENE6 were obtained from Roche diagnostics GmbH. Mouse anti-calnexin antibody was purchased from BD biosciences. Mouse anti-HA (12CA5) and anti-myc (9E10) antibodies were produced in our core facility as ascitic fluids.
ET analysis of β 1 AR
The evolutionary importance was calculated by ET (69) from sequences of TM domain of 139 bioamine receptors, which consist of 29 α-adrenergic, 26 β-adrenergic, 30 serotonergic, 30 dopaminergic, 18 cholinergic and 6 histaminic receptors. Protein sequences corresponding to TM domains, TM1 (Trp35 to Gln64), TM2 (Pro71 to His100), TM3 (Pro107 to Val139), TM4 (Asn151 to Val173), TM5 (Asn200 to Gln225), TM6 (Glu247 to Thr277), and TM7 (Ile286 to Tyr306) of bovine rhodopsin (Swissprot: OPSD_BOVIN), were analyzed. Among the residues ranking in top 50%, structural clusters located on the protein surface were picked up as candidates of dimerization interfaces. An ET server is available at http://mammoth.bcm.tmc.edu/.
Receptor constructs
Vectors encoding β 1 AR-GFP10, β 1 AR-Rluc and β 2 AR-Rluc have been described previously (55) . In order to construct N-terminally HA-tagged β 1 AR (HA-β 1 AR) and myc-tagged β 2 AR (myc-β 2 AR), βAR sequence was amplified using a primer harboring the Kozak and Hemagglutinin Tag (YPYDVPDYA) or c-myc Epitope Tag (EQKLISEEDL) sequences, and subcloned into pcDNA3.1/Zeo (+). β 1 AR-eGFP was obtained from β 1 AR-GFP10 by subcloning the coding sequence of β 1 AR into pEGFP-N1 expression vector (Clontech). β 1 ARVenus and β 2 AR-Venus were created by exchanging the C-terminal-fused fluorophore of β 2 AR-GFP10 (55) with the Venus variant of eYFP (70) . HA-β 1 AR-Rluc, HA-β 1 AR-Venus, and myc-β 2 AR-Venus, which were used in the analysis of cell surface receptor expression, were created by replacing the N-terminal region of Rluc-or Venus-fused constructs with the corresponding coding sequence of HA-or myc-tagged constructs. Mutant β 1 ARs (L105F, I194W, V179W, W183F and W183A) were created using QuikChange XL site-directed mutagenesis kit (Stratagene).
Cell culture and transfection
HEK293 cells were maintained in Dulbecco's modified Eagle's medium supplemented with 5% fetal bovine serum, 100 units/ml penicillin and 100 μg/ml streptomycin at 37°C in a humidified atmosphere, with 5% CO 2 . Transient transfections were performed using FuGENE6, according to the manufacturer's protocol. Cells were harvested 48 h after transfection to perform the indicated assay.
BRET 2 assay
BRET assay was carried out as previously described (71) . Briefly, HEK293 cells resuspended in PBS were distributed in 96-well microplate (Corning No. 3917). The luciferase substrate, DeepBlueC coelenterazine, was added at a final concentration of 5 μM. Signals were detected at 370-450 nm and 500-530 nm using a modified TopCount NXT plate reader (Packard Bioscience) equipped with the appropriate band pass filters. BRET signals were calculated as the ratio of the light emitted by GFP10 (500-530 nm) over the light emitted by Rluc (370-450 nm). The expression level of the energy acceptor (GFP10) tagged proteins were measured as total fluorescence using a FluoroCount fluorometer (Packard) with an excitation filter at 400 nm and an emission filter at 510 nm. The expression level of the energy donor (Rluc) tagged protein was measured using a LumiCount luminometer (Packard) in the presence of 5 μM coelenterazine h. BRET signals were drawn as a function of the GFP10/Rluc total expression ratio, as previously described (55) . BRET 50 values were identified as the GFP/Rluc ratio leading to 50% of the maximal BRET.
Confocal microscopy
HEK293 cells were plated on poly-D-lysine coated coverslips and transfected with the indicated plasmids; 48 h after transfection, coverslips were washed with PBS and fixed with 3% paraformaldehyde for 15 min. Receptor distribution was generally assessed by direct fluorescence detection of the fused eGFP or Venus in non-permeabilized cells. When indicated, cells were permeabilized with PBS containing 0.2% BSA and 0.3% triton-X100 for 10 min followed by immunolabeling using mouse anti-calnexin (1:100) as primary antibody and Alexa Fluor 594 conjugated goat anti-mouse immunoglobulin (IgG) as secondary antibody. Confocal microscopy images were obtained using a Zeiss LSM510 META laser scanning microscope.
Laser excitation and emission filters used were as follows: eGFP: λ ex = 488 nm, λ em = 505-530 nm; Venus: λ ex = 514 nm, λ em = 530-600 nm; Alexa Fluor 594: λ ex = 543 nm, λ em = 575-630 nm.
Cell surface receptor expression assay (fixed cells)
HEK293 cells were plated on poly-D-lysine coated dishes, transfected with WT or W183A mutant HA-β 1 AR-Rluc and treated or not with 10 μM alprenolol for 4 or 24 h, prior to measurement. To determine receptor cell surface expression, cells were washed twice with PBS, blocked with PBS containing 1% bovine serum albumin, and labeled with mouse anti-HA antibody (1:1000). Cells were then washed with PBS, fixed with 3% paraformaldehyde and cell surface expression level detected using horseradish peroxidase-conjugated anti-mouse IgG antibody (1:1000) and SIGMA FAST™ o-phenylenediamine dihydrochloride peroxidase substrate kit. From the same batch of cells, total receptor expression level was determined by measuring total luminescence in the presence of 5 μM coelenterazine h using a LumiCount reader (Packard). Cell surface receptor expression was determined as the ratio of cell surface over total expression.
Cell surface receptor expression assay (non-fixed cells)
HEK293 cells were co-transfected with HA-WTβ 1 AR-Venus or myc-WTβ 2 AR-Venus, with or without W183Aβ 1 AR. To determine WT receptor cell surface expression, cells were detached, resuspended in PBS and labeled with mouse anti-HA antibody (1:1000) or mouse anti-myc antibody (1:1000). Cells were then washed with PBS and cell surface expression level detected using horseradish peroxidase-conjugated anti-mouse IgG antibody (1:1000) and SIGMA FAST™ o-phenylenediamine dihydrochloride peroxidase substrate kit. Total receptor expression level was determined by measuring Venus fluorescence. In order to exclude the effect on expression level of W183Aβ 1 AR co-expression, cell surface receptor expression was determined as the ratio of cell surface over total expression and expressed as a percentage of surface expression level estimated from a regression curve using surface expression and total expression in the absence of W183Aβ 1 AR.
Intracellular cAMP measurement
cAMP accumulation in living cells was determined by ELISA based assay using CatchPoint™ cAMP assay kit (Molecular Devices, CA). In brief, HEK293 cells were transfected with WT or W183A mutant β 1 AR, and treated or not with 10 μM alprenolol for 16 h. Cells were then detached in PBS containing 0.5 mM EDTA and washed extensively with PBS. Cells (5 × 10 3 cells) were incubated with increasing concentrations of dobutamine, a selective β 1 AR agonist, for 15 min at 37°C in phosphate-buffered saline containing 10 mM glucose and 750 μM 3-isobutyl-1-methyl-xanthine. cAMP production was determined according to standard kit protocol and detected as fluorescence (excitation 530 nm and emission 590 nm) using the FlexStation II microplate reader (Molecular Devices).
Deglycosylation assay of β 1 AR
HEK293 cells transfected with WT or W183A mutant were solubilized in 85 mM NaCl, 75 mM Tris-HCl pH 7.4, 12.5 mM MgCl 2 , 0.5 % N-dodecyl maltoside, 5 μg/ml leupeptin, 10 μg/ ml benzamidine, and 5 μg/ml soybean trypsin inhibitor. Samples were sonicated and centrifuged at 5000 × g for 5 min. Supernatants were immunoprecipitated using anti-HA antibody (12CA5 1:100) and protein G-sepharose overnight at 4°C. The immune complex were pelleted by brief centrifugation, washed twice with solubilization buffer, and resuspended into assay buffer (50 mM sodium phosphate pH 5.5, 50 mM EDTA, 1% 2-mercaptoethanol, 0.5% Ndodecyl maltoside, 0.2 mM Phenylmethanesulfonyl fluoride, 5 μg/ml leupeptin, 10 μg/ml benzamidine and 5 μg/ml soybean trypsin inhibitor). Samples were incubated 24 h at 37°C in The trace residue clusters identified correspond to group of residues ranking into the top 50% of the ET analysis that map onto specific surface domains of the receptor. The ranking of each residue represents relative evolutionary importance, where 1 indicates absolute invariance. Three significant clusters were identified: cluster 1 includes residues spanning TM 2, TM3 and TM4, whereas clusters 2 and 3 are composed of residues within TM5, TM6 and TM7. The residues numbering corresponds to the position within the human β 1 AR. BRET 50 represent the GFP/Rluc ratio leading to 50% of the maximal BRET signal and were calculated from BRET titration curve fitting using non-linear regression of three to four independent experiments. *p < 0.01. Cells were co-transfected with fixed amount of WTβ 1 AR-Rluc or WTβ 2 AR-Rluc and increasing amount of WT-or W183Aβ 1 AR-GFP10. BRET titration curves were generated for each pair by combining data of three to four independent experiments and were used to calculate BRET 50 values for each pairs using non-linear regression. The luciferase and fluorescence levels reached in these experiments were similar for each conditions (β 1 AR-Rluc = 491 ± 83 fmol; β 2 AR-Rluc = 583 ± 101 fmol; WTβ 1 AR-GFP10 = 0-2039 fmol; W183Aβ 1 AR-GFP10 = 0-1420 fmol). *p < 0.001. A) Cells expressing W183Aβ 1 AR-eGFP were treated or not with 10 μM alprenolol for 24 h, labeled with anti-calnexin antibody as a marker of the ER and prepared for confocal fluorescence microscopy. Confocal images show the localization of W183Aβ 1 AR (green) and calnexin (red) and their merged co-localization (yellow). The bar = 10 μm. B) Cells expressing HA-β 1 AR-Rluc were treated or not with 10 μM alprenolol for 4 or 24 h. Cells were then split and either labeled with anti-HA antibody for cell surface (ELISA) detection or exposed to 5 μM coelenterazine h for detection of total expression (luminescence). The cell surface immunoreactivity/luciferase activity ratio was used as an index of the fraction of the total β 1 AR population that was targeted at the cell surface. The data are expressed as percentage of the cell surface fraction observed for the WT receptor and represent the mean ± SEM of three independent experiments. *p < 0.01. C) Cells expressing WT or mutant HA-β 1 AR were treated or not with 10 μM alprenolol for 16 h. Receptors were immunoprecipetated with a mouse anti-HA antibody, treated or not with endoH, resolved on SDS-PAGE and immunoblotted with a rat anti-HA antibody. The data shown are representative of three independent experiments. 
